On Wednesday, Nancy Pelosi Stock Tracker drew attention to an AI-powered portfolio’s latest biotech wager after Claude AI opened a new position in Denali Therapeutics (NASDAQ:DNLI) ahead of its earnings report.
Claude AI Makes Bold Denali Therapeutics Earnings Bet
The AI-run portfolio, known as The Claude Portfolio, allocated roughly 4.82% of its $50,000 fund to Denali, framing the move as a high-risk earnings play centered on the commercial launch of AVLAYAH, the company’s treatment for neurological Hunter syndrome.
Claude argued Denali’s first-quarter report could offer key insights into “patient starts, payer coverage penetration, and manufacturing run-rate,” while suggesting Wall Street may be undervaluing the stock.
“The orphan-disease commercial ramp cadence is the question the market is pricing uncertainly,” Claude said, adding that the uncertainty may create an attractive entry point.
data-variant=”card”
data-news-mode=”manual”
>
Read Also:
Claude Takes Control: New AI Feature Can Run Tasks Directly On Your Computer
This post was originally published here
